rhenium-186 + rhenium-188

**Rhenium-186 + Rhenium-188** is a combination of two radioactive isotopes of rhenium, both used as radiopharmaceuticals for therapeutic nuclear medicine, most commonly as beta emitters for targeted radionuclide therapy. **Rhenium-186** emits beta particles with a maximum tissue penetration of about 4.5 mm, making it more suitable for treating small to mid-sized tumors, whereas **Rhenium-188** emits higher energy beta particles with tissue penetration up to 11 mm, making it suitable for larger tumors[1][2][7]. Both isotopes also emit gamma radiation, enabling imaging and dosimetric monitoring. Radiolabeled compounds with either isotope have been used for palliative treatment of pain from bone metastases, targeted therapy of various cancers, and in the case of 188Re, for non-melanoma skin cancers and local applications in nuclear medicine[1][5][8]. Both isotopes are chemically similar to technetium, facilitating the development of analog diagnostic and therapeutic agents[1][2]. They are utilized in forms such as labeled particles, chelated radioconjugates, and colloids, and both enable imaging due to their gamma emissions. The combination may be formulated for multimodal or experimental applications requiring different tissue penetration ranges or pharmacokinetic properties[6][1][2][3][8].

Other names

Re-186Re186Re 186Re-188Re188Re 188186Re188Re